BiotechTube

Tamsulosin HCl + Solifenacin Succinate + EC905

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phase 1

Conditions

Phase 1, Healthy, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms

Trial Timeline

Mar 1, 2009 → Jul 1, 2009

NCT ID
NCT02634489

About Tamsulosin HCl + Solifenacin Succinate + EC905

Tamsulosin HCl + Solifenacin Succinate + EC905 is a phase 1 stage product being developed by Astellas Pharma for Phase 1. The current trial status is completed. This product is registered under clinical trial identifier NCT02634489. Target conditions include Phase 1, Healthy, Benign Prostatic Hyperplasia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02634489Phase 1Completed

Competing Products

20 competing products in Phase 1

See all competitors
ProductCompanyStageHype Score
TERN-701Terns PharmaceuticalsPhase 1/2
38
solifenacin succinate + mirabegron + mirabegron/solifenacin succinateAstellas PharmaPhase 1
33
Graceptor®Astellas PharmaPre-clinical
23
Lemborexant + PlaceboEisaiApproved
85
BIW-8962Kyowa KirinPhase 1/2
41
AcalabrutinibAstraZenecaPhase 1/2
41
Sacituzumab tirumotecanMerckPhase 2
52
progesterone + ProgesteroneMerckApproved
85
AsciminibNovartisPre-clinical
23
NilotinibNovartisPhase 3
77
Imatinib mesylateNovartisPhase 3
77
Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib MesylateNovartisPhase 3
77
ribociclib + TrametinibNovartisPhase 1
33
NilotinibNovartisApproved
85
ImatinibNovartisPhase 3
77
NilotinibNovartisApproved
85
GleevecNovartisPhase 2
52
Nilotinib + RuxolitinibNovartisPhase 1/2
41
ABL001NovartisPhase 3
77
asciminibNovartisPhase 2
52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85